Research Use Only / Third-Party Analytical Testing / Per-Batch Documentation / Materials Shipped from the USA
Search Account 0 Cart
Thymosin Alpha-1 (TA-1) research material
Vial · Research materialHelio®
Helio / Materials / Longevity
Longevity Research

Thymosin Alpha-1 (TA-1)

Thymosin Alpha-1 (TA-1, also called Tα1 or Thymalfasin) is a 28-amino-acid, N-terminally acetylated peptide originally isolated from the thymic tissue fraction Thymosin Fraction 5. Sequence-identical to the endogenous human peptide, it carries a molecular formula of C129H215N33O55 and a molecular weight of approximately 3,108 g/mol (CAS 62304-98-7). Its acetylated N-terminus is a defining structural feature confirmed by mass spectrometry.

TA-1 is one of the most extensively studied immunomodulatory peptides in the thymosin family. Research literature examines its interactions with Toll-like receptor signaling pathways, its influence on dendritic cell and T-cell maturation, and its modulation of cytokine networks and natural killer cell activity. Because it maps to endogenous thymic biology, it is widely used as a reference tool in immunology and infectious-disease models. Supplied for laboratory research use only.

Identification
  • MaterialThymosin Alpha-1 (TA-1)
  • Research AreaLongevity
  • PresentationVial
  • Available Sizes5mg
  • CAS Number62304-98-7
  • Molecular FormulaC129H215N33O55
  • Molecular Weight3108.3 g/mol
  • TypeAcetylated 28-residue peptide (thymic peptide fragment)
  • Receptor / TargetToll-like receptors (notably TLR2 / TLR9) and innate/adaptive immune modulation
  • PubChem CID16130571 →
Amino Acid Sequence

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

Analytical Data
  • Purity (HPLC)≥99%
  • Identity (MS)Confirmed to specification
  • TestingAccredited (ISO 17025) third-party laboratory
  • CertificateView COA · Lot 26125001 →
From$59.95

Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.

Key Characteristics
Molecular FormulaC129H215N33O55
Molecular Weight3,108.3 g/mol
CAS Number62304-98-7
PubChem CID16130571
SequenceAc-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (28 aa, acetylated)
Receptor / TargetToll-like receptors (TLR2 / TLR9); innate and adaptive immune modulation
FormLyophilized powder (5mg vial)
SolubilitySoluble in water and bacteriostatic water
StorageStore lyophilized cold and protected from light; -20°C to -80°C for long-term storage
StabilityLyophilized form stable at room temperature short-term; reconstituted material refrigerated at 4°C
Research Context
Innate immune signalingStudied for engagement of Toll-like receptors (TLR2/TLR9) and downstream activation of innate immune pathways.
T-cell maturationInvestigated for influence on thymocyte and T-lymphocyte differentiation and function.
Dendritic cell functionExamined for effects on dendritic cell maturation and antigen presentation in immunological models.
Cytokine modulationExplored for reported modulation of interferon and interleukin cytokine profiles.
Infectious disease & vaccine modelsUsed as an immunomodulatory reference peptide in antiviral, sepsis, and vaccine-adjuvant research.
Anti-tumor immunityStudied in preclinical oncology models for natural killer cell and effector-cell activity.
Research Findings

Research on Thymosin Alpha-1 describes pleiotropic immunomodulatory activity: enhancement of T-cell and dendritic cell maturation, augmentation of natural killer cell activity, and modulation of cytokine expression through Toll-like receptor signaling. It is one of the most clinically investigated thymic peptides internationally, with a substantial literature spanning viral infection, sepsis, and oncology models.

Reported effects derive from cell-culture systems, animal models, and clinical studies conducted outside the United States; findings are context-dependent and not established for U.S. therapeutic use. This material is offered strictly as a research reagent.

History

Thymosin Alpha-1 was first isolated and characterized in the 1970s by Allan Goldstein and colleagues from Thymosin Fraction 5, a thymic tissue extract. It was among the first thymic peptides to be fully sequenced and synthesized, and under the name thymalfasin it has been developed and studied internationally as an immunomodulator across infectious-disease and oncology contexts.

References
  1. Goldstein AL, et al. Thymosin alpha1: chemistry, mechanism of action, and applications. Ann N Y Acad Sci. 2007.
  2. Romani L, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326-338.
  3. King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151-178.
  4. PubChem Compound Summary for CID 16130571, Thymalfasin. National Center for Biotechnology Information.

View compound profile on NIH PubChem →

Cited literature refers to laboratory and preclinical research. Thymosin Alpha-1 (TA-1) is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Why researchers choose Helio
99%+ PurityHPLC-verified every batch
Accredited TestingIndependent ISO 17025 laboratory
Per-Batch COADocumentation tied to your lot
Made in the USADiscreet, protected shipping
Related

More in Longevity

View area →